HOME >> BIOLOGY >> NEWS
REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement

, data was analyzed from the REMICADE 5 mg/kg every eight week maintenance arm of each trial, the only regimen common to both EXPRESS and EXPRESS II. At week 10, after infusions at weeks 0, 2, and 6, the proportions of patients achieving PASI 75 were 80 percent versus three percent of placebo patients for EXPRESS and 75 percent versus two percent of placebo patients for EXPRESS II, (both P < 0.001 versus placebo). At week 10, the proportions of patients achieving PASI 90, or nearly complete skin clearance, were 57 percent versus one percent of placebo patients for EXPRESS and 45 percent versus 0.5 percent of placebo patients for EXPRESS II, (both P < 0.001 versus placebo). PASI 75 responses achieved at week 10 were maintained through week 26 in both EXPRESS and EXPRESS II (81 percent and 78 percent of patients achieved at least PASI 75 improvement from baseline, respectively), and the majority of patients achieved PASI 75 at week 50 in the REMICADE 5 mg/kg every eight-week maintenance groups.

"These data show great potential for REMICADE in the treatment of a disease that often carries great physical and emotional challenges," said Robert Matheson, MD, Oregon Medical Research Center, and study investigator. "The potential of achieving nearly complete skin clearance is exciting and holds great promise for patients with this difficult to treat disease."

Investigators reported that at week 10 patients in both EXPRESS and EXPRESS II receiving REMICADE experienced improvements in the Dermatology Life Quality Index (DLQI) and Physician's Global Assessment (PGA), measures of quality of life and psoriasis severity, respectively. In both studies, following 5 mg/kg induction therapy, REMICADE-treated patients experienced a median improvement of nine points in DLQI, a change that is considered to be a clinically meaningful decrease in psoriasis-related burden for the patient, compared to no improvement for placebo patients (REMICADE vs. placebo, -9.0 ve
'"/>

Contact: Michael Parks
215-983-8000
Centocor, Inc.
3-Mar-2006


Page: 1 2 3

Related biology news :

1. Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients
2. Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis
3. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
4. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
5. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
6. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
7. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
8. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
9. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
10. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
11. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA

Post Your Comments:
(Date:10/29/2014)... consequence of chemotherapy will benefit from a major research ... prevents hair loss. , The research is being now ... manufacturing company, Paxman Coolers, of Fenay Bridge, Huddersfield, in ... Huddersfield. , The research will be led by key ... pharmacology of cancer treatment, which he will use towards ...
(Date:10/29/2014)... but they also need protection from its harmful rays, just ... in plants that shields them from sun damage. Now, in ... Society , one team reports on the mechanics of how ... at Purdue University note that the harsh ultraviolet radiation plants ... DNA and, as a result, hinder plant growth. Biochemical ...
(Date:10/29/2014)... German . ... Peter Schlögelhofer at the Max F. Perutz Laboratories (MFPL) ... of Vienna dived into the process of meiosis in ... an inversion of the standard meiotic phases. The researchers ... Nature Communications . , Meiosis is the two-step series ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2Meiotic cell division 'the other way round' 2
(Date:10/30/2014)... (PRWEB) October 30, 2014 The report ... Chemicals), by Application (Cosmetics & Toiletries, and Soaps & ... to 2019”, has defined and segmented the Fragrance Ingredients ... trends in terms of value. The market has been ... North America, Europe, Asia-Pacific, Latin America, and Rest of ...
(Date:10/30/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the China Naltrexone ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... October 30, 2014 Grace Century portfolio project, ... A. Manganello, Chairman of the Board, to the National ... The appointment was made by the Ministry of Health on ... 2014. , More than a year after Bahamian ... , Prime Minister Perry Christie said the government has completed ...
Breaking Biology Technology:Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
Cached News: